TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 01/27/22

Complete Safety Data Anticipated by End of 1Q 2022 Safety Management Committee Has Recommended 12 mg as Phase 2 Dose Niclosamide is a Potent Inhibitor of SARS-CoV-2 with Activity Against Multiple Variants AUSTIN, Texas, Jan. 27, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceu...

TFF Pharmaceuticals (TFFP -2.4%) announces the full readout of safety and pharmacokinetic (PK) data from its Phase 1b study of Inhaled Voriconazole Powder (TFF VORI) in asthma patients. Systemic PK data following repeated dosing with an 80 mg twice daily dose showed no statistical differ...

Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma Pharmacokinetic Data Revealed No Differences in Patients Using Bronchodilato...

Progenity is transitioning away from molecular testing operations to focus on the development of biotherapeutics. In this respect, the third quarter's financials were pivotal to the transformation strategy as it translated into a reduction in operational expenses as planned. With ...

AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that i...

TFFP is suffering due to a lack of human trial data. They may have multiple human trial data readouts by next year. The market may begin to notice this company once that happens. For further details see: TFF Pharmaceuticals: Data Desert May Be A Thing Of The Past By 2022...

After a long and painful downside, TFFP's stock has finally delivered a one-day outperformance with respect to the big Covid plays due to the Omicron variant. The next question is whether this is just another blip as was the case in July when there were positive clinical trials r...

Image source: The Motley Fool. TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) Q3 2021 Earnings Call Nov 15, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: TFF Pharmaceuticals, Inc. (TFFP) Q3 2021 Earnings Call Transcript...

TFF Pharmaceuticals, Inc. (TFFP) Q3 2021 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Glenn Mattes - President & Chief Executive Officer Dr. Dale Christensen - Director of Clinical Development Dr. Bill Williams - University of T...

TFF Pharmaceuticals (NASDAQ:TFFP): Q3 GAAP EPS of -$0.34 misses by $0.13. Revenue of $0.05M misses by $1.08M. Press Release For further details see: TFF Pharmaceuticals EPS misses by $0.13, misses on revenue